Sensei Biotherapeutics, Inc. (SNSE) intrinsic value & 10-year financials
Sensei Biotherapeutics, Inc. (SNSE) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -59.2%
- Free cash flow (FY2025)
- -$20.5M
SNSE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$21.1M | -$16.72 | -$20.5M | — | -111.7% |
| FY2024 | — | -$30.2M | -$1.20 | -$24.8M | — | -76.2% |
| FY2023 | — | -$34.1M | -$1.22 | -$32.2M | — | -46.3% |
| FY2022 | — | -$48.6M | -$1.58 | -$39.3M | — | -41.8% |
| FY2021 | — | -$36.8M | -$1.33 | -$32.3M | — | -107.2% |
| FY2020 | — | -$20.1M | — | -$18.9M | — | 27.8% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Sensei Biotherapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Sensei Biotherapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -59.3% ROIC.
Sensei Biotherapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Sensei Biotherapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.